RT Journal
A1 Kuehn BM
T1 STudies may not provide clear view of antipsychotics
JF JAMA
JO JAMA
YR 2012
FD April 18
VO 307
IS 15
SP 1572
OP 1572
DO 10.1001/jama.2012.499
UL http://dx.doi.org/10.1001/jama.2012.499
AB 

              There is evidence that clinical trial sponsors and researchers may avoid submitting for publication studies that have negative findings. Less commonly, some journals may hesitate to publish trials with negative results. Such bias can skew the evidence base so that an intervention appears more effective than it is. To assess whether such bias exists in the evidence base supporting antipsychotic medications, Erick H. Turner, MD, of the Oregon Health & Science University in Portland, and his colleagues looked at studies examining atypical antipsychotic drugs for the treatment of schizophrenia or schizoaffective disorder. The researchers compared the published studies with those that had been submitted to the US Food and Drug Administration (FDA) to gain approval to market the drugs for these indications (Turner EH et al. PLoS Med. 2012;9[3]:e1001189).